Aegera Therapeutics, Inc., a Montreal-based clinical stage biotechnology company focused on developing targeted therapeutics for oncology and pain, announced today the full drawdown of a CDN$7m debt facility provided by Investissement Quebec.
The facility was provided to fund the attainment of significant developments in Aegera‘s AEG35156 oncology program and AEG33773 diabetic neuropathic pain program, both of which are currently being tested in randomized Phase 2 clinical trials in Canada, the United States and Europe, and to provide additional working capital to the company.
FinSMEs
23/09/2009